In addition, ID-AraC + G-CSF SD also significantly improved mobilization efficacy in patients with MM, and it is associated with highest probability of being best regimen in consideration of both the number of total CD34+ cells collected and the successful rate of achieving optimal mobilization target. This evidence concerns the gene CD34 and Miyoshi myopathy.